Research programme: cancer diagnostics - Bayer Healthcare Pharmaceuticals/Stanford University
Latest Information Update: 26 Jan 2015
Price :
$50 *
At a glance
- Originator Bayer HealthCare Pharmaceuticals; Stanford University
- Class Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Mar 2010 Preclinical development is ongoing
- 28 Nov 2006 Preclinical trials in Diagnostic imaging in USA (unspecified route)
- 28 Nov 2006 Preclinical trials in Cancer (diagnosis) in USA (unspecified route)